After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in 2008. However, following US patent expiries of both the acute migraine market leading brand, Imitrex (sumatriptan; GlaxoSmithKline), and leading prophylactic Topamax (topiramate; Johnson & Johnson), the market value plummeted by almost $1.5 billion from 2008 to $3.6 billion in 2009.
Key reasons to purchase this title
- Quantify the current and future size of the migraine market.
- Understand the country-specific impact of key events in the migraine market during the forecast period 2010 to 2019.
- Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2010 to 2019.
